You are here:

Forthcoming Submission: teduglutide (Revestive)

Indication: Treatment of patients aged 1 year and above with short bowel syndrome.

Drug Details

Drug Name: teduglutide (Revestive)
Drug Manufacturer: Shire Pharmaceuticals
BNF Category:
Submission type: Full submission
Patient Interest Group
Submission Deadline:
6/11/2017
SMC Meeting Date: 9/01/2018
Advice Due: 9/04/2018

Back